Vicore Pharma Holding AB (publ) research snapshot
VCRE AI stock analysis reads Vicore Pharma as a high-risk, high-upside clinical-stage biopharmaceutical company developing first-in-class angiotensin II type 2 receptor agonists (ATRAGs). The lead candidate buloxibutid (C21) is fully enrolled in the global 52-week Phase 2b ASPIRE trial (NCT06588686) for idiopathic pulmonary fibrosis (IPF), with topline data expected around mid-2027, and the company began trading its sponsored Level 2 ADR on Nasdaq under VCRE on July 1, 2026. At the August 4, 2026 data cutoff, the latest verified quote snapshot was $14.15 per ADR, and cross-verified market capitalization was approximately $398 million based on the company reported share count. The stock is near the lower end of its short post-listing range ahead of the readout, supported by cash runway into the second half of 2028. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$14.15
Market cap
$398 million
AI score
42 / 100
Rating
Speculative clinical-stage biotech, fully enrolled Phase 2b awaiting mid-2027 data
Trend status
ADR near the lower end of its post-listing range ahead of the ASPIRE readout
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Vicore is a clinical-stage biotech with no approved products or recurring revenue. Business quality cannot be assessed until ASPIRE Phase 2b delivers topline data around mid-2027. | Low |
| Moat | Vicore holds ATRAG intellectual property, FDA Orphan Drug and Fast Track designations, a Japan orphan designation, and an MHRA Innovation Passport, but any moat is unproven until clinical validation and regulatory approval are achieved. | Low |
| Management | A strengthened team completed enrollment in ASPIRE ahead of schedule, secured FDA designations, raised capital, listed an ADR on Nasdaq, and promoted CMO, CTO, and CBO roles plus a new CSO, but it has not yet commercialized a product or generated meaningful revenue. | Medium-low |
| Financial trend | Vicore generates negligible revenue (SEK 0.6 million in Q1 2026) and burns cash on R&D. Net loss was SEK 108.6 million in Q1 2026 and SEK 477.5 million in FY2025. Cash of SEK 1,059.8 million (about USD 111.4 million) at March 31, 2026 supports runway into the second half of 2028. | Medium |
| Valuation | At $14.15 with a cross-verified market cap of about $398 million, VCRE trades entirely on option value for buloxibutid success. Standard valuation multiples are not meaningful for a pre-revenue biotech. | Low |
| Technical trend | The ADR began trading on July 1, 2026 and has ranged from approximately $13.40 to $17.80 since listing. It is near the low end of that short range, reflecting cautious positioning ahead of ASPIRE data. | Medium-low |
| Risk level | Extreme. Binary Phase 2b readout around mid-2027, no approved products, no revenue, cash burn, potential future dilution, single-pipeline dependency, and an IPF market with approved therapies and competing candidates. | High |
| AI confidence | Medium for descriptive facts and financial data; low for forward scenarios and valuation because clinical-stage biotech is inherently binary. | Medium data confidence |
| Investment certainty | Low. Vicore is suitable only for high-risk-tolerant investors who understand binary clinical trial risk and the possibility of total capital loss. | Low |
VCRE AI stock forecast
The VCRE AI stock forecast uses scenario ranges around the $14.15 ADR price and the binary nature of the ASPIRE Phase 2b readout expected around mid-2027. The framework produces a bearish area near $3 to $5, a base case centered on the current $11 to $17 range, and a bullish scenario in the $28 to $40 range. All scenarios depend on the buloxibutid data, financing, and IPF market dynamics.
$28 to $40
More likely if the ASPIRE Phase 2b trial meets its primary FVC endpoint with statistically significant and clinically meaningful results, the buloxibutid safety profile is clean, and the company secures partnership or financing to advance to Phase 3.
$11 to $17
More likely if the stock trades range-bound while awaiting the mid-2027 topline data, with price driven by cash position, analyst updates, US ADR flows, and general biotech sentiment rather than fundamental news.
$3 to $5
More likely if the ASPIRE trial misses primary endpoints, shows safety concerns, or faces delays. A failure could significantly impair the stock given Vicores single-pipeline dependency.
VCRE AI technical analysis
VCRE AI technical analysis is limited by the short ADR trading history, which began July 1, 2026, and by low ADR trading volume. As of the latest quote snapshot (July 8, 2026 close), VCRE traded near $14.15, closer to the bottom of its $13.40 to $17.80 range since listing, with below-average volume reflecting cautious positioning before the mid-2027 ASPIRE Phase 2b readout.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $14.15 | Latest verified close snapshot near $14.15 on the Nasdaq ADR, with pre-market around $13.49 on the most recent snapshot. |
| Near support | $13.40 | The low end of the range since the July 1, 2026 ADR listing is near $13.40, serving as immediate support. A break below would signal weak positioning ahead of data. |
| Deeper support | $10 area | If $13.40 fails, the next psychological support is the $10 area, below the range established since listing. |
| Near resistance | $15.00 to $15.50 | The short ADR history has seen early resistance in this zone, where moving averages likely sit given the limited price range. |
| Range high | $17.80 | The high end of the range since listing near $17.80 is the breakout reference if positive news emerges. |
| Volume | Average volume near 263K shares | Average daily volume on the ADR is modest at approximately 263,000 shares, making large moves possible on modest news-driven buying or selling. |
| Volatility | High, typical for clinical-stage biotech | Biotech stocks with binary catalysts can move 20% to 50% or more on trial data announcements, regardless of prior technical patterns. |
| Invalidation | Close below $13.40 on above-average volume | A decisive break below the post-listing low on elevated volume would indicate that market expectations for ASPIRE have deteriorated significantly. |
VCRE AI trading strategy
The VCRE AI trading strategy is a risk-management framework for monitoring a binary clinical-stage biotech catalyst with a confirmed mid-2027 readout timeline. It is not personal advice and should be paired with trial timeline tracking, cash runway monitoring, fresh chart data, position sizing, and the understanding that total capital loss is possible.
Monitor the ASPIRE Phase 2b topline data timeline around mid-2027, including the estimated primary completion in May 2027. Position size must reflect the binary nature of the readout. Track Vicore press releases, clinicaltrials.gov updates, and IPF conference presentations for timeline visibility.
Define maximum loss before entry. Clinical-stage biotech binary events can result in 60% to 80% or more downside on a failed trial. No position should be sized where such a loss is unacceptable.
If VCRE continues to trade in the $13.40 to $17.80 range without catalyst news, the setup is purely technical with wide bid-ask spreads on the ADR. Low-frequency monitoring is appropriate.
Avoid averaging down into a stock whose primary value driver is a binary, unreadable clinical outcome. Range trades in pre-data biotech carry asymmetric downside risk.
After ASPIRE data, reassess based on whether the primary FVC endpoint was met, the magnitude of effect, safety profile, competitive positioning against Ofev and Esbriet, and the path to Phase 3 and regulatory filing.
Do not chase a post-data spike without understanding the data quality and the remaining regulatory and commercial pathway. Positive Phase 2b data does not guarantee Phase 3 or FDA approval success.
Investment research summary
Vicore is developing oral drugs that activate the AT2 receptor to treat fibrotic lung diseases. Patients and doctors would pay for a therapy that slows IPF progression with fewer side effects than current treatments.
Any moat is hypothetical until clinical validation. ATRAG IP, US Orphan Drug and Fast Track status, a Japan orphan designation, and an MHRA Innovation Passport provide some protection, but the IPF market already has approved therapies (Ofev, Esbriet) and a competitive pipeline.
The thesis fails if buloxibutid does not meet its Phase 2b FVC endpoint around mid-2027, shows an unfavorable safety profile, requires a larger or longer Phase 3 program than expected, or is outperformed by competing IPF candidates.
Leadership has completed enrollment in ASPIRE, secured regulatory designations, raised capital, and listed a US ADR, but the team has not yet taken a product through approval and commercialization.
IPF is a serious unmet medical need with a growing patient population, but the competitive landscape includes established therapies and multiple pipeline candidates targeting different mechanisms.
At roughly a $398 million cross-verified market cap with zero revenue, VCRE is priced on option value. Margin of safety does not exist in any traditional sense. Investment depends entirely on the probability-weighted value of buloxibutid success.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VCRE ADR price | $14.15 (latest verified close snapshot; pre-market near $13.49) | Yahoo Finance quote snapshot | July 8, 2026 close snapshot |
| Market capitalization | Approximately $398 million, computed as $14.15 x 28.15M ADR shares (281,525,593 ordinary shares at a 10:1 ADR ratio); Yahoo reported about $453M and TradingView about $327M on their own bases | Vicore share register + financial_rigor.py market cap verification | August 4, 2026 |
| FY2025 revenue | Approximately $413K (SEK 3.8 million) | TradingView fundamentals snapshot / Vicore annual report | August 4, 2026 |
| Q1 2026 revenue | SEK 0.6 million (Jan-Mar 2026) | Vicore Q1 2026 interim report | August 4, 2026 |
| FY2025 net loss | Approximately -$51.7 million (SEK -477.5 million) | TradingView fundamentals snapshot / Vicore annual report | August 4, 2026 |
| Q1 2026 net loss | SEK -108.6 million (Jan-Mar 2026) | Vicore Q1 2026 interim report | August 4, 2026 |
| Cash position | SEK 1,059.8 million (about USD 111.4 million) at March 31, 2026; cash runway into H2 2028 | Vicore Q1 2026 interim report | August 4, 2026 |
| EPS (TTM) | Approximately -$0.18 to -$0.20 per ordinary share as reported by vendors; about -$1.8 per ADR at the 10:1 ratio | Yahoo Finance and TradingView statistics snapshots | August 4, 2026 |
| ADR program | Sponsored Level 2 ADR, ratio 10 ordinary shares per ADR, symbol VCRE on Nasdaq since July 1, 2026, with Citi as depositary | Vicore Pharma ADR page | August 4, 2026 |
| Range since listing | $13.40 to $17.80 | Yahoo Finance range snapshot | July 8, 2026 close snapshot |
| Average volume | Approximately 263,000 shares | Yahoo Finance statistics snapshot | August 4, 2026 |
| Lead program | Buloxibutid (C21) ATRAG in Phase 2b ASPIRE trial (NCT06588686) for IPF, fully enrolled with 378 participants, active not recruiting, primary completion estimated May 2027 | ClinicalTrials.gov record and Vicore Pharma corporate website | August 4, 2026 |
| Employees | Approximately 40 full-time | Yahoo Finance profile snapshot | August 4, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell VCRE stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Clinical-stage biotech investing carries the risk of total capital loss. Always verify current filings, trial data, prices, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
